A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.
Charlotte Jacobs, Gary H. Lyman, E Vélez-García et al. · Journal of Clinical Oncology · 1992
PURPOSE: To determine whether combination chemotherapy is superior to single agents for recurrent/metastatic head and neck cancer, we compared the efficacy and toxicity of cisplatin (CP) and fluorouracil (5-FU), alone and in combination in a phase III trial. PATIENTS AND METHODS: Two hundred forty-nine patients with recurrent head and neck cancer were randomized to one of three treatments: CP (100 mg/m2) and 5-FU (1 g/m2 x 4), CP, or 5-FU every 3 weeks. RESULTS: The overall response rate to the combination (32%) was superior to that of CP (17%) or 5-FU (13%) (P = .035). Response was associated with good performance status (PS) but not with primary site, site of recurrence, histology, prior irradiation, or relative dose intensity. Median time to progression was less than 2.5 months, and there was no significant difference in median survival (5.7 months) among the groups. By multivariate analysis, patients with better PS and poorly differentiated tumors had superior survival. Hematologic toxicity and alopecia were worse in the combination arm. CONCLUSION: Although the response rate to the combination of CP plus 5-FU was superior to that achieved with single agents, survival did not improve.
Cited by 628 works. doi:10.1200/jco.1992.10.2.257
Authors
- Charlotte Jacobs
- Gary H. Lyman
- E Vélez-García
- Kasi S. Sridhar
- Howard S. Höchster
- Lawrence T. Goodnough
- Joanne E. Mortimer
- Lawrence H. Einhorn
- Lee Schacter
References
- Nonparametric Estimation from Incomplete Observations
- Regression Models and Life-Tables
- The Statistical Analysis of Failure Time Data.
- Prognostic Factors for Survival in Patients With Inoperable Lung Cancer 2
- The importance of dose intensity in chemotherapy of metastatic breast cancer.
- Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck
- The role of chemotherapy in the management of cancer of the head and neck: A review
- Factors that affect response to chemotherapy and survival of patients with advanced head and neck cancer
- A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck
- A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck